Robert Metz
Director/Board Member presso Cures Within Reach
Profilo
Robert W.
Metz is on the board of Cures Within Reach.
In the past he occupied the position of Senior VP-Business Operations & Government Affairs at Horizon Therapeutics Plc SVP-Business Operations & Human Resources at Horizon Pharma, Inc. and Vice President-Business Operations at Horizon Therapeutics, Inc. (both are subsidiaries of Horizon Therapeutics Plc), Principal at NeoPharm, Inc., Principal at MedPointe, Inc., Vice President-Commercial Operations at IDM Pharma, Inc. and Principal at Reliable Biopharmaceutical Corp.
Mr. Metz received an undergraduate degree from Marietta College.
Posizioni attive di Robert Metz
Società | Posizione | Inizio |
---|---|---|
Cures Within Reach | Director/Board Member | - |
Precedenti posizioni note di Robert Metz
Società | Posizione | Fine |
---|---|---|
HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY | Chief Operating Officer | 01/10/2019 |
Horizon Therapeutics, Inc.
Horizon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Horizon Therapeutics is a late stage biopharmaceutical company focused on the development of prescription drugs for mild to moderate pain relief. It is creating novel therapies through innovative combinations of existing pharmaceutical products. The Company is building a portfolio of proprietary formulations that seek to improve safety, efficacy, and patient compliance. | Corporate Officer/Principal | 05/04/2010 |
IDM Pharma, Inc.
IDM Pharma, Inc. Pharmaceuticals: MajorHealth Technology IDM Pharma, Inc. develops products for the destruction of cancer cells. Its products activate the immune system or prevent recurrence by triggering adaptive immune response. The company was founded in established on October 1987 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 01/06/2009 |
Horizon Pharma, Inc.
Horizon Pharma, Inc. Pharmaceuticals: MajorHealth Technology Horizon Pharma, Inc. discovers and develops medicines for the treatment of chronic inflammatory diseases. It is a specialty pharmaceutical company that has developed and is commercializing DUEXIS and RAYOS, both of which target unmet therapeutic needs in arthritis, pain and inflammatory diseases. The company products include DUEXIS (ibuprofen and famotidine) Tablets, is a proprietary, single-tablet combination of the non-steroidal anti-inflammatory drug ibuprofen and the histamine H2-receptor antagonist famotidine; RAYOS (prednisone) delayed-release tablets, known as LODOTRA outside the U.S., is a proprietary delayed-release formulation of low-dose prednisone for the treatment of moderate to severe, active RA in adults, particularly when accompanied by morning stiffness. Horizon Pharma was founded on March 23, 2010 and is headquartered in Deerfield, IL. | Compliance Officer | 30/05/2013 |
RBC Post Corp.
RBC Post Corp. Pharmaceuticals: MajorHealth Technology Reliable Biopharmaceutical Corp. manufactures and develops pharmaceutical ingredients. It offers products in various categories, including active product ingredients, nucleic acid chemistry, enzymes and natural products, carbohydrate chemistry and ultra pure biochemicals. Its products are used in generic injectable drugs which treat cancer, heart diseases, hypertension, anxiety and other serious and life threatening illnesses. The company was founded by Robert S. Vaters and William G. Ash in 1968 and is headquartered in St. Louis, MO. | Corporate Officer/Principal | - |
Formazione di Robert Metz
Marietta College | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 8 |
---|---|
NeoPharm, Inc.
NeoPharm, Inc. BiotechnologyHealth Technology NeoPharm, Inc. engages in the research, development, and commercialization of drugs for the treatment of various cancers and other diseases. The company has built its drug development program around two proprietary technology platforms, a tumor-targeting toxin platform which includes development for a new indication of Pulmonary Fibrosis, and a novel NeoLipid liposomal drug delivery system. It has advanced five drug product candidates in various stages of clinical and pre clinical development for the treatment of cancer and one drug product candidate in pre-clinical development for treatment of interstitial pulmonary fibrosis and asthma. NeoPharm was founded in May 15, 1900and is headquartered in Lake Bluff, IL. | Health Technology |
Horizon Therapeutics Plc
Horizon Therapeutics Plc Pharmaceuticals: MajorHealth Technology Horizon Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland. | Health Technology |
MedPointe, Inc.
MedPointe, Inc. Pharmaceuticals: MajorHealth Technology MedPointe, Inc. develops, markets, and sells therapeutics. The company's products include respiratory, allergy, central nervous system, cough/cold, and pediatric products. The company was founded by James S. Burns and Anthony H. Wild in 2001 and is headquartered in Somerset, NJ. | Health Technology |
IDM Pharma, Inc.
IDM Pharma, Inc. Pharmaceuticals: MajorHealth Technology IDM Pharma, Inc. develops products for the destruction of cancer cells. Its products activate the immune system or prevent recurrence by triggering adaptive immune response. The company was founded in established on October 1987 and is headquartered in Cambridge, MA. | Health Technology |
Horizon Therapeutics, Inc.
Horizon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Horizon Therapeutics is a late stage biopharmaceutical company focused on the development of prescription drugs for mild to moderate pain relief. It is creating novel therapies through innovative combinations of existing pharmaceutical products. The Company is building a portfolio of proprietary formulations that seek to improve safety, efficacy, and patient compliance. | Health Technology |
RBC Post Corp.
RBC Post Corp. Pharmaceuticals: MajorHealth Technology Reliable Biopharmaceutical Corp. manufactures and develops pharmaceutical ingredients. It offers products in various categories, including active product ingredients, nucleic acid chemistry, enzymes and natural products, carbohydrate chemistry and ultra pure biochemicals. Its products are used in generic injectable drugs which treat cancer, heart diseases, hypertension, anxiety and other serious and life threatening illnesses. The company was founded by Robert S. Vaters and William G. Ash in 1968 and is headquartered in St. Louis, MO. | Health Technology |
Horizon Pharma, Inc.
Horizon Pharma, Inc. Pharmaceuticals: MajorHealth Technology Horizon Pharma, Inc. discovers and develops medicines for the treatment of chronic inflammatory diseases. It is a specialty pharmaceutical company that has developed and is commercializing DUEXIS and RAYOS, both of which target unmet therapeutic needs in arthritis, pain and inflammatory diseases. The company products include DUEXIS (ibuprofen and famotidine) Tablets, is a proprietary, single-tablet combination of the non-steroidal anti-inflammatory drug ibuprofen and the histamine H2-receptor antagonist famotidine; RAYOS (prednisone) delayed-release tablets, known as LODOTRA outside the U.S., is a proprietary delayed-release formulation of low-dose prednisone for the treatment of moderate to severe, active RA in adults, particularly when accompanied by morning stiffness. Horizon Pharma was founded on March 23, 2010 and is headquartered in Deerfield, IL. | Health Technology |
Cures Within Reach |